Heart, Lung & Vascular Research Institute
Clinical Trials
20190184: EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction
This study is currently enrolling.
This study is being done to learn whether regular healthcare, combined with early treatment with a cholesterol lowering drug called evolocumab (Repatha) reduces heart attack, stroke, procedures to improve blood flow and death, ...
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)
This study is currently enrolling.
You are being asked to take part in a research study of an experimental treatment called sotatercept. “Experimental” means that sotatercept is currently being tested and is not approved for sale by any Health Authorities/regula ...
A Phase 3 Study of Sotatercept in Participants with PAH WHO FC III or FC IV at High Risk of Mortality
This study is currently enrolling.
Pulmonary arterial hypertension (PAH) is a disease affecting the blood vessels of the lungs. PAH leads to increased pressure in the blood vessels of the lungs which further leads to straining of the right side of the heart. ...
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation
This study is currently enrolling.
The purpose of this research study is to compare the effects of an experimental drug, milvexian, to the comparator drug, apixaban, to determine if it is safe and useful in reducing the risk of stroke and blood clots outside the ...
ALLAY-HF: Safety and Efficacy of the Alleviant System for No-Implant Interatrial Shunt Creation in Patients with Chronic Heart Failure
This study is currently enrolling.
To evaluate the safety and efficacy of the Alleviant ALV1 System in patients with chronic heart failure (HF) and preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF), who remain symptomatic despite a ...
Assessment of Implantable CCM in the Heart Failure Group with Higher Ejection Fraction
This study is currently enrolling.
Your doctor has diagnosed you with HF. You are being asked to consider voluntary participation in a research study of CCM treatment with the Optimizer System, sponsored by Impulse Dynamics (USA) Inc. CCM with the Optimizer Syst ...
Assessment of the Safety and Efficacy of a Combined Cardiac Contractility Modulation and Implantable Cardioverter Defibrillator Device for Subjects with Heart Failure and Reduced Ejection Fraction
This study is currently enrolling.
This research study is designed to determine if the combination of CCM and ICD, as an investigational device (OPTIMIZER INTEGRA CCM-D System) can effectively defibrillate and treat episodes of VT/VF should any occur.
BAROSTIM THERAPY in Heart Failure with Reduced Ejection Fraction A Post-Market Registry with the BAROSTIM NEO System
This study is currently enrolling.
You are invited to participate in a Registry to track the performance of the BAROSTIM NEO Device. You are being invited because you have been implanted with the Device because of your condition called heart failure. In this Reg ...
CATALYST - Clinical trial of atrial fibrillation patients comparing left atrial appendage occlusion therapy to non-vitamin K antagonist oral anticoagulants
This study is currently enrolling.
The purpose of this research study is to compare the safety and effectiveness of the Amulet device compared to non-vitamin K antagonist oral anticoagulants (NOACs) for ischemic stroke risk reduction. NOACs are a class or type ...